|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang HC, Hu CH, Tang MC, Wang WS, Chen PM
and Su Y: Thymosin beta4 triggers an epithelial-mesenchymal
transition in colorectal carcinoma by upregulating integrin-linked
kinase. Oncogene. 26:2781–2790. 2007. View Article : Google Scholar
|
|
3
|
Gjerdrum C, Tiron C, Høiby T, Stefansson
I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT,
et al: Axl is an essential epithelial-to-mesenchymal
transition-induced regulator of breast cancer metastasis and
patient survival. Proc Natl Acad Sci USA. 107:1124–1129. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Song Y, Washington MK and Crawford HC:
Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal
transition in pancreatic cancer. Cancer Res. 70:2115–2125. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee TK, Poon RT, Yuen AP, Ling MT, Kwok
WK, Wang XH, Wong YC, Guan XY, Man K, Chau KL, et al: Twist
overexpression correlates with hepatocellular carcinoma metastasis
through induction of epithelial-mesenchymal transition. Clin Cancer
Res. 12:5369–5376. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Giannelli G, Fransvea E, Bergamini C,
Marinosci F and Antonaci S: Laminin-5 chains are expressed
differentially in metastatic and nonmetastatic hepatocellular
carcinoma. Clin Cancer Res. 9:3684–3691. 2003.PubMed/NCBI
|
|
7
|
Lee J, Choi JH and Joo CK: TGF-β1
regulates cell fate during epithelial-mesenchymal transition by
upregulating survivin. Cell Death Dis. 4:e7142013. View Article : Google Scholar
|
|
8
|
O'Connor JW and Gomez EW: Cell adhesion
and shape regulate TGF-beta1-induced epithelial-myofibroblast
transition via MRTF-A signaling. PLoS One. 8:e831882013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wendt MK, Balanis N, Carlin CR and
Schiemann WP: STAT3 and epithelial-mesenchymal transitions in
carcinomas. JAK-STAT. 3:e289752014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kamran MZ, Patil P and Gude RP: Role of
STAT3 in cancer metastasis and translational advances. Biomed Res
Int. 421821:2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hills CE and Squires PE: The role of TGF-β
and epithelial-to mesenchymal transition in diabetic nephropathy.
Cytokine Growth Factor Rev. 22:131–139. 2011.PubMed/NCBI
|
|
12
|
Książkiewicz M, Markiewicz A and Zaczek
AJ: Epithelial-mesenchymal transition: A hallmark in metastasis
formation linking circulating tumor cells and cancer stem cells.
Pathobiology. 79:195–208. 2012. View Article : Google Scholar
|
|
13
|
Levy DE and Darnell JE Jr: Stats:
transcriptional control and biological irnpact. Nat Rev Mol Cell
Biol. 3:651–662. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu Y, Sarkissyan M and Vadgama JV:
Epithelial-Mesenchymal Transition and Breast Cancer. J Clin Med.
5:2–18. 2016. View Article : Google Scholar
|
|
15
|
Brivio S, Cadamuro M, Fabris L and
Strazzabosco M: Epithelial-to-mesenchymal transition and cancer
invasiveness: What can we learn from cholangiocarcinoma. J Clin
Med. 4:2028–2041. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nalluri SM, O'Connor JW and Gomez EW:
Cytoskeletal signaling in TGFβ-induced epithelial-mesenchymal
transition. Cytoskeleton. 72:557–569. 2015. View Article : Google Scholar
|
|
17
|
Cheng GZ, Zhang WZ, Sun M, Wang Q, Coppola
D, Mansour M, Xu LM, Costanzo C, Cheng JQ and Wang LH: Twist is
transcriptionally induced by activation of STAT3 and mediates STAT3
oncogenic function. J Biol Chem. 283:14665–14673. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang S, Sun WY, Wu JJ, Gu YJ and Wei W:
Decreased expression of the type III TGF-β receptor enhances
metastasis and invasion in hepatocellullar carcinoma progression.
Oncol Rep. 35:2373–2381. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yeh YH, Wang SW, Yeh YC, Hsiao HF and Li
TK: Rhapontigenin inhibits TGF-β-mediated epithelial mesenchymal
transition via the I3K/AKT/mTOR pathway and is not associated with
HIF-1α degradation. Oncol Rep. 35:2887–2895. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Piccirillo R and Giavazzi R: Inactivating
STAT3: Bad for tumor, good for muscle. Cell Cycle. 14:939–940.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wake MS and Watson CJ: STAT3 the oncogene
- still eluding therapy. FEBS J. 282:2600–2611. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Colomiere M, Ward AC, Riley C, Trenerry
MK, Cameron-Smith D, Findlay J, Ackland L and Ahmed N: Cross talk
of signals between EGFR and IL-6R through JAK2/STAT3 mediate
epithelial-mesenchymal transition in ovarian carcinomas. Br J
Cancer. 100:134–144. 2009. View Article : Google Scholar
|
|
23
|
Li CJ, Li YC, Zhang DR and Pan JH: Signal
transducers and activators of transcription 3 function in lung
cancer. J Cancer Res Ther. 9(Suppl 2): S67–S73. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu A, Zhao F, Wang J, Zhao Y, Luo Z, Gao
Y and Shi J: Regulation of TRPM7 function by IL-6 through the JAK2
STAT3 signaling pathway. PLoS One. 11:e0152120–e0152132. 2016.
View Article : Google Scholar
|
|
25
|
Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang
QC, Zhang YJ, Lu R, Chen YX and Fang JY: Inhibition of JAK1,
2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces
tumor cell invasion in colorectal cancer cells. Neoplasia.
10:287–297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu RY, Zeng Y, Lei Z, Wang L, Yang H, Liu
Z, Zhao J and Zhang HT: JAK/STAT3 signaling is required for
TGF-β-induced epithelial-mesenchymal transition in lung cancer
cells. Int J Oncol. 44:1643–1651. 2014. View Article : Google Scholar : PubMed/NCBI
|
